Contradictions Unveiled: Krystal Biotech's Q2 2025 Earnings Call Reveals Conflicting Insights on VYJUVEK Sales and Market Strategy

Generado por agente de IAAinvest Earnings Call Digest
lunes, 4 de agosto de 2025, 12:51 pm ET1 min de lectura
KRYS--
Impact of insurance changes on VYJUVEK sales, patient compliance and drug holiday expectations, European launch timeline and pricing strategy, patient count and U.S. market penetration, and compliance rate and patient behavior are the key contradictions discussed in Krystal Biotech's latest 2025Q2 earnings call.



VYJUVEK Revenue and Sales Force Expansion:
- Krystal BiotechKRYS-- reported Q2 net VYJUVEK revenue of $96 million, bringing total net VYJUVEK

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios